BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26960957)

  • 21. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
    N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
    Suzuki T; Takeuchi M; Saeki H; Yamazaki S; Koga H; Abe D; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
    Clin Ther; 2010 Mar; 32(3):527-31. PubMed ID: 20399989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield.
    Seshadri T; Gook D; Lade S; Spencer A; Grigg A; Tiedemann K; McKendrick J; Mitchell P; Stern C; Seymour JF
    Br J Cancer; 2006 Apr; 94(7):1007-10. PubMed ID: 16570049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
    Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case with Hodgkin lymphoma and fronto-temporal lobular degeneration (FTLD)-like dementia facilitated by chemotherapy.
    Katsumata R; Sagawa R; Akechi T; Shinagawa Y; Nakaaki S; Inagaki A; Okuyama T; Akazawa T; Furukawa TA
    Jpn J Clin Oncol; 2010 Apr; 40(4):365-8. PubMed ID: 20026458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
    Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH; Anter AH; Awad IA
    Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
    Lipton JH; Gospodarowicz M; Reingold S
    Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
    Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
    J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy.
    Hodgson DC; Pintilie M; Gitterman L; Dewitt B; Buckley CA; Ahmed S; Smith K; Schwartz A; Tsang RW; Crump M; Wells W; Sun A; Gospodarowicz MK
    Hematol Oncol; 2007 Mar; 25(1):11-5. PubMed ID: 17036376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification.
    Shalom-Paz E; Almog B; Shehata F; Huang J; Holzer H; Chian RC; Son WY; Tan SL
    Reprod Biomed Online; 2010 Oct; 21(4):566-71. PubMed ID: 20822957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilateral sudden hearing loss following ABVD protocol.
    Tazi I; Nafil H; Mahmal L
    J Cancer Res Ther; 2014; 10(1):212. PubMed ID: 24762521
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP.
    Anselmo AP; Cartoni C; Bellantuono P; Maurizi-Enrici R; Aboulkair N; Ermini M
    Haematologica; 1990; 75(2):155-8. PubMed ID: 1694156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network.
    Bujan L; Walschaerts M; Brugnon F; Daudin M; Berthaut I; Auger J; Saias J; Szerman E; Moinard N; Rives N; Hennebicq S
    Fertil Steril; 2014 Sep; 102(3):667-674.e3. PubMed ID: 25044088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
    Filatova LV; Plotnikova AA; Gershanovich ML; Semiglazova TIu
    Vopr Onkol; 2013; 59(2):59-65. PubMed ID: 23814851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease.
    Amadori S; Papa G; Anselmo AP; Fidani P; Mandelli F; Biagini C
    Cancer Treat Rep; 1983 Jun; 67(6):603-4. PubMed ID: 6190561
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
    van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.